Home

Statistics on the Marshall Protocol

The primary function of the Marshall ProtocolA curative medical treatment for chronic inflammatory disease. Based on the Marshall Pathogenesis. (MP) study site is to learn how the MP affects and improves the health of patients with a variety of inflammatory conditions. As of February 2009, there are about 1,000 patients who post in their progress reports on the MP study site. Many patients have recovered sufficiently to rejoin the work force, and subsequently become so busy that they no longer report progress. Autoimmunity Research FoundationNon-profit foundation dedicated to exploring a pathogenesis and therapy for chronic disease. is currently in the process of partnering with a hospital which has the resources necessary to manage a large-scale cohort study of the MP.

Response rate

One of the observations seen in the online progress reports–and confirmed in independent reports coming from MP physicians whose patients do not post on the study site–is that nearly everyone on the MP experiences immunopathologyA temporary increase in disease symptoms experienced by Marshall Protocol patients that results from the release of cytokines and endotoxins as disease-causing bacteria are killed.. Some estimate this number to be as high as 99%; others are more conservative and say it is 95%. Immunopathology is the calculated rise and fall in symptoms and is a sign that bacteria are being killed. Immunopathology seems to be independent of the diagnosis given to the disease.

Recovery rate

The best data collected thus far is from a 2008 survey of MP patients with autoimmune diseases, the methodology of which is described here. That data was presented by Capt. Tom Perez, MPH, at the 2008 International Congress on Autoimmunity.

ARF is currently in the process of partnering with a hospital which has the resources necessary to manage a large-scale cohort study of the MP.

home/patients/cohort_statistics.txt · Last modified: 10.13.2018 by sallieq
© 2015, Autoimmunity Research Foundation. All Rights Reserved.